Skip to main content
Premium Trial:

Request an Annual Quote

Large Scale Biology Adds Nine Patents to IP Portfolio

NEW YORK, Nov. 15 – Large Scale Biology was issued nine new patents the company plans to use in its proteomics, functional genomics, and biomanufacturing operations, the company announced Thursday.

The patents issued to the Vacaville, Calif.-based company include US Patent No 6,254,834 for, according to the company, “distinguishing infectious agents, for identifying known viral pathogens, and for discovering and characterizing unknown viral pathogens.”

“Expanding our rights in the area of viral detection enables us to develop new means of identifying and tracking infections earlier, with important public health safety implications, as well as potential savings for the public and private medical care system,” John Fowler, president of Large Scale Biology, said in a statement.

Other patents include technology applicable to automated 2-D gel electrophoresis, agricultural genomics, and biomanufacturing, including extracting sugars and pharmaceutical proteins from plants.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.